The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

Neurolixis Announces Publications Demonstrating Effects of NLX-112 in Parkinson's Disease Models


(February 25, 2016) - Neurolixis, Inc. announced the recent publication of two scientific articles demonstrating robust effects of the Company’s lead drug candidate, NLX-112, in rodent models of Parkinson’s disease. As described in these publications, NLX-112, a selective serotonin 5-HT1A receptor agonist, exhibited potent activity in parkinsonian rats, producing an immediate and complete abolition of L-DOPA-induced dyskinesia (LID). Read more



Article Archive

back